Physician profile
Katelyn Roper
NPI 1255983805
$1,128.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $164 · 2023: $400 · 2024: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $413.13 | 2023-2024 | Qelbree, Qelbree |
| Abbvie INC. | $192.02 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $120.38 | 2022-2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $88.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $61.81 | 2023-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $53.55 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $50.12 | 2022-2024 | Spravato |
| Neos Therapeutics, LP | $47.89 | 2023-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $39.08 | 2023-2024 | Auvelity |
| Corium, LLC | $29.59 | 2024 | Azstarys |
| Lundbeck LLC | $19.43 | 2023 | Abilify Asimtufii |
| Almatica Pharma LLC | $13.44 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Roper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.